Canada - engelsk - Health Canada

auro pharma inc - daptomycin - powder for solution - 500mg - daptomycin 500mg

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - daptomycin -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - daptomycin -

Malta - engelsk - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

Malta - engelsk - Medicines Authority

uab norameda meistru 8a, vilnius lt-02189, lithuania - daptomycin - powder for solution for injection/infusion - daptomycin 500 milligram(s) - antibacterials for systemic use

Canada - engelsk - Health Canada

teva canada limited - daptomycin - powder for solution - 500mg - daptomycin 500mg - cyclic lipopeptides

Malta - engelsk - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

Malta - engelsk - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - daptomycin - powder for solution for infusion or injection - daptomycin 500 mg - antibacterials for systemic use

Malta - engelsk - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - daptomycin, quantity: 350 mg - inhalation, powder for - excipient ingredients: sodium hydroxide; citric acid - daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).,consideration should be given to official guidance on the appropriate use of antibacterial agents.,daptomycin is not indicated for the treatment of pneumonia.,adult patients (?18 years of age):,complicated skin and skin structure infections,pfizer daptomycin is indicated for the treatment of adults (? 18 years of age) with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,staphylococcus aureus bloodstream infections (bacteraemia),pfizer daptomycin is indicated in adults (?18 years of age) for staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (rie), caused by methicillin-susceptible and methicillin-resistant isolates.,the efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to staphylococcus aureus has not been demonstrated. in the setting of staphylococcus aureus bacteraemia (sab), if a focus of infection is diagnosed as left-sided endocarditis after daptomycin therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy.,paediatric patients (1 to 17 years of age):,daptomycin is not indicated for treatment of patients less than 1 year of age.,daptomycin has not been studied in treatment of infective endocarditis in children.,complicated skin and skin structure infections,pfizer daptomycin is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,staphylococcus aureus bloodstream infections (bacteraemia),pfizer daptomycin is indicated in paediatric patients (1 to 17 years of age) with staphylococcus aureus bacteraemia not due to pneumonia, caused by daptomycin-susceptible isolates. empiric treatment should be reviewed based on the results of susceptibility testing. prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of staphylococcus aureus bacteraemia.